Cases & Deals

  • Home
  • Practices
  • Ultragenyx files ANDA patent suit against three generic-drug manufacturers involving DOJOLVI®

Share

Ultragenyx files ANDA patent suit against three generic-drug manufacturers involving DOJOLVI®

September 2024

Client(s) Ultragenyx Pharmaceutical Inc.

Jones Day represents plaintiff Ultragenyx Pharmaceutical Inc. in asserting claims of patent infringement under the Hatch-Waxman Act involving a life-saving pharmaceutical product known as Dojolvi® (triheptanoin) against three generic manufacturers seeking to market generic versions of triheptanoin oral liquid. Dojolvi® is used to treat long-chain fatty acid oxidation disorders (LC-FAOD), which are caused by genetic defects and for which there is no cure. People with LC-FAOD have difficulty producing enough energy because of their body's inability to use long-chain fatty acids as an energy source. Dojolvi® provides an alternate source of energy that dramatically improves these patients' lives.

Ultragenyx Pharmaceutical Inc. et al. v. Navinta LLC et al., No. 2-24-cv-09483 (D.N.J.)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.